The quiet side of EU novel foods: how ‘ordinary’ innovations are overshadowed by extreme cases

Background: Novel foods (NFs) are often seen as radical innovations that challenge ethical norms and cultural expectations, fueling polarized debates on safety and acceptability. Yet, many authorised NFs have entered markets quietly, without triggering adverse consumer reactions. Aim: This commentary illustrates the ‘quiet side’ of NFs by highlighting authorised ingredients that have been integrated into EU food systems with limited public visibility, and by discussing how media narratives and cognitive biases shape this asymmetry. Methods: We examined authorised NFs including human-identical milk oligosaccharides (3-Fucosyllactose, 3′-Sialyllactose Sodium Salt), DHA-rich oil from Schizochytrium sp., Yarrowia lipolytica biomass, chia seeds, and prebiotic oligosaccharides (GOS, XOS, IMOS). Data were collected from regulatory dossiers, scientific literature, and market reports to assess safety, functional properties, and integration into conventional diets. Results: Many NFs are not radically different from conventional foods but provide nutritional, technological, and environmental benefits. Our analysis highlights a pronounced gap between public perception—often shaped by sensationalized narratives—and scientific evaluation confirming safety and functionality. Conclusions: Recognizing the low-profile success of many NFs emphasizes the importance of clear and evidence-based science communication. Educating consumers about the safety, benefits, and integration of NFs can reduce polarized opinions and foster informed acceptance. By bridging innovation, regulation, and consumer understanding, these insights support the responsible development of sustainable, nutritionally enhanced, and technologically advanced food systems.